WO2003084467A3 - Epitope constructs comprising antigen presenting cell targeting mechanisms - Google Patents

Epitope constructs comprising antigen presenting cell targeting mechanisms Download PDF

Info

Publication number
WO2003084467A3
WO2003084467A3 PCT/US2003/010033 US0310033W WO03084467A3 WO 2003084467 A3 WO2003084467 A3 WO 2003084467A3 US 0310033 W US0310033 W US 0310033W WO 03084467 A3 WO03084467 A3 WO 03084467A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen presenting
presenting cell
cell targeting
epitope constructs
targeting mechanisms
Prior art date
Application number
PCT/US2003/010033
Other languages
French (fr)
Other versions
WO2003084467A2 (en
Inventor
Ronald M Burch
Daniel A Soltis
Original Assignee
Euro Celtique Sa
Ronald M Burch
Daniel A Soltis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa, Ronald M Burch, Daniel A Soltis filed Critical Euro Celtique Sa
Priority to MXPA04009554A priority Critical patent/MXPA04009554A/en
Priority to CA002478930A priority patent/CA2478930A1/en
Priority to IL16428103A priority patent/IL164281A0/en
Priority to AU2003224819A priority patent/AU2003224819A1/en
Priority to JP2003581707A priority patent/JP2005536987A/en
Publication of WO2003084467A2 publication Critical patent/WO2003084467A2/en
Publication of WO2003084467A3 publication Critical patent/WO2003084467A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to products and methods to elicit a targeted immune response. In particular, the invention relates to epitope constructs that comprise antigen presenting cell-targeting mechanisms.
PCT/US2003/010033 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms WO2003084467A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA04009554A MXPA04009554A (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms.
CA002478930A CA2478930A1 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms
IL16428103A IL164281A0 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms
AU2003224819A AU2003224819A1 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms
JP2003581707A JP2005536987A (en) 2002-04-01 2003-04-01 Epitope construct containing antigen-presenting cell targeting mechanism

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36945402P 2002-04-01 2002-04-01
US60/369,454 2002-04-01

Publications (2)

Publication Number Publication Date
WO2003084467A2 WO2003084467A2 (en) 2003-10-16
WO2003084467A3 true WO2003084467A3 (en) 2006-07-20

Family

ID=28791953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/010033 WO2003084467A2 (en) 2002-04-01 2003-04-01 Epitope constructs comprising antigen presenting cell targeting mechanisms

Country Status (6)

Country Link
JP (1) JP2005536987A (en)
AU (1) AU2003224819A1 (en)
CA (1) CA2478930A1 (en)
IL (1) IL164281A0 (en)
MX (1) MXPA04009554A (en)
WO (1) WO2003084467A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401472A4 (en) * 2001-05-25 2005-04-06 Univ Jefferson Alternative splice forms of proteins as basis for multiple therapeutic modalities
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
CA2509684A1 (en) * 2002-07-03 2004-01-15 Sanofi Pasteur Limited Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer
CA2514058C (en) 2003-01-24 2014-05-13 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
ES2415336T3 (en) * 2003-04-11 2013-07-25 Survac Aps Therapeutic Cancer Vaccine
GB0318247D0 (en) * 2003-08-05 2003-09-10 Royal Veterinary College Antigen delivery system
KR20070116650A (en) * 2005-03-23 2007-12-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Novel composition
JP5241012B2 (en) * 2005-07-15 2013-07-17 ノバルティス アーゲー PAMPS, pathogen-related molecular pattern
EP2305827A1 (en) * 2005-11-14 2011-04-06 Université Laval Cancer antigen MAGE-A9 and uses thereof
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US20090186042A1 (en) * 2006-02-27 2009-07-23 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
WO2008009309A1 (en) 2006-07-17 2008-01-24 Glaxosmithkline Biologicals S.A. Influenza vaccine
ES2657480T3 (en) * 2006-08-11 2018-03-05 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
EP2462947B1 (en) * 2007-03-26 2019-03-13 Academisch Ziekenhuis Leiden h.o.d.n. LUMC PRAME derived peptides and immunogenic compositions comprising these
SI2567707T1 (en) * 2007-07-27 2017-01-31 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
EP2356131A4 (en) * 2008-12-08 2012-09-12 Tegopharm Corp Masking ligands for reversible inhibition of multivalent compounds
FR2955773B1 (en) * 2010-02-01 2017-05-26 Commissariat A L'energie Atomique MOLECULAR COMPLEX FOR TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AND ITS APPLICATIONS FOR VACCINATION
US9109007B2 (en) 2010-08-18 2015-08-18 Purdue Pharma L.P. MHC-I restricted epitopes containing non-natural amino acid residues
KR20150128900A (en) 2013-03-15 2015-11-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Vaccines having an antigen and interleukin-23 as an adjuvant
WO2016057986A1 (en) * 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
US10238741B2 (en) 2014-10-10 2019-03-26 The Trustees Of Columbia University In The City Of New York Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof
KR102041032B1 (en) * 2015-06-01 2019-11-27 레버 제네틱스 컴퍼니 리미티드 Vaccine composition for swine genital respiratory syndrome and swine circovirus associated diseases
WO2017165542A1 (en) * 2016-03-22 2017-09-28 University Of Florida Research Foundation, Inc. Methods, kit, and compositions for enhancing cellular therapy
CA3056212A1 (en) * 2016-04-07 2017-10-12 Bostongene Corporation Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
CN110996970A (en) 2017-06-02 2020-04-10 亚利桑那州立大学董事会 Method of creating personalized cancer vaccines
US20200209241A1 (en) 2017-09-15 2020-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FONG L. ET AL.: "Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy", PROC. NATL. ACAD. SCI. USA, vol. 98, no. 15, 17 January 2001 (2001-01-17), pages 8809 - 8814, XP003001078 *
HUARTE E. ET AL.: "Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements", CLIN. CANCER RES., vol. 8, July 2002 (2002-07-01), pages 2336 - 2344, XP002345510 *
NAGORSEN D. ET AL.: "Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her2/neu, and carcinoembryonic antigen in patients with colorectal cancer", CANCER RES., vol. 60, 1 September 2000 (2000-09-01), pages 4850 - 4854, XP003001079 *
THOMSON S.A. ET AL.: "Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design", J. VIROL., vol. 72, no. 3, March 1998 (1998-03-01), pages 2246 - 2252, XP002128492 *
WANG H. ET AL.: "Rapid antibody responses by low-dose, single-step dendritic cell-targeted immunization", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 2, 18 January 2000 (2000-01-18), pages 847 - 852, XP001206541 *

Also Published As

Publication number Publication date
AU2003224819A1 (en) 2003-10-20
CA2478930A1 (en) 2003-10-16
IL164281A0 (en) 2005-12-18
MXPA04009554A (en) 2005-01-25
JP2005536987A (en) 2005-12-08
WO2003084467A2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
WO2003084467A3 (en) Epitope constructs comprising antigen presenting cell targeting mechanisms
WO2005002621A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
TW200515916A (en) Chimeric antigens for breaking host tolerance to foreign antigens
WO2000056360A3 (en) Vaccine against antigens from bacteriae
WO2005037190A3 (en) Multiplex vaccines
WO2006071989A3 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
WO2003059381A3 (en) Immunogenic preparations and vaccines on the basis of mrna
ATE381893T1 (en) AROMA PARTICLES
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
IL154913A0 (en) Composition comprising immunogenic microparticles
IS4518A (en) New vaccine formulation
WO2006041933A3 (en) Improved vaccines
WO2003094960A3 (en) Mucosal combination vaccines for bacterial meningitis
WO2006090291A3 (en) Method for expanding cd4+ cd25+ t regulatory cells
WO2003090696A3 (en) Methods and products for mucosal delivery
WO2001081609A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
WO2000062801A3 (en) Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv)
WO2004005476A3 (en) Nucleic acid compositions for stimulating immune responses
WO2005000884A8 (en) Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
WO2004031210A3 (en) Optimized multi-epitope constructs and uses thereof
AU2003302165A8 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
AU2003242535A1 (en) Improved polysaccharide and glycoconjugate vaccines
AU2007272785A8 (en) Methods to elicit, enhance and sustain immune responses against MHC class-I restricted epitopes, for prophylactic or therapeutic purposes
WO2005122739A3 (en) Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2478930

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003224819

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003721511

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/009554

Country of ref document: MX

Ref document number: 2003581707

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003721511

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)